Ref ID: 2746
Author:
J. STONE1, S. HOLLAND1, P. WICKERSHAM1, P. DEUTSCH1, G. WINCHELL1, M. HESNEY1, R. MILLER1, A. FREEMAN1, S. DILZER2, K. LASSETER2
Author address:
1Merck Research Laboratories, West Point, PA, 2Clinical Pharmacology Associates, Miami, FL.
Full conference title:
ICAAC 41st
Abstract:
Background: Caspofungin (CancidasTM, MK-0991, L-743,872) is a parenteral antifungal agent that inhibits the synthesis of 1,3 b-D glucan, an essential component of the fungal cell wall.
Methods: The potential for drug interactions between caspofungin and tacrolimus (FK-506) was evaluated in a placebo-controlled, randomized, Phase I study. Part (1) was a 2-period, parallel-panel study in which healthy subjects received tacrolimus (2 doses of 0.1 mg/kg oral capsules administered 12 hours apart, n=12) or placebo (n=5) alone in Period 1 and again on Day 10 of caspofungin 70 mg IV daily in Period 2. In Part (2), parallel panels of healthy subjects received tacrolimus (2 doses of 0.1 mg/kg 12 hours apart, n=8) or placebo (n=8) on Days 1 and 10 of caspofungin 50 mg IV daily.
Results: The geometric mean ratio (90% CI) for caspofungin plasma AUC(0-24hr) under coadministration relative to administration alone was 1.00 (0.96, 1.04) for Part (1) and 1.05 (0.96, 1.15) for Part (2), based on a mixed-model analysis that evaluated pharmacokinetic data obtained on Days 9 and 10 in both the coadministration and the placebo-control panels. The geometric mean ratio (90% CI) for tacrolimus whole blood AUC(0-12hr) in Period 2 (coadministration) relative to Period 1 (administration alone) was 0.80 (0.72, 0.89) for Part (1), based on a combined analysis of morning and evening doses. Reductions of similar magnitude were also seen for tacrolimus CMAX and C12hr. Conclusions: Tacrolimus does not alter the pharmacokinetics of caspofungin. Caspofungin modestly reduces whole blood concentrations of tacrolimus. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
Abstract Number: NULL
Conference Year: 2001
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Kimihide Muragaki1, Kenji Uehara1, Toru Takahashi2,3, Youhei Yamagata3 and Keietsu Abe1,3*
2011
NULL
n/a
-
v
Ryota Hattori , Mayumi Matsusita-Morita , Sawaki
Tada , Junichiro Marui , Ikuyo Furukawa , Satoshi Suzuki , Hitoshi Amano , Hiroki Ishida , Youhei Yamagata , Michio Takeuchi , Ken-Ichi Kusumoto2011
63)
n/a
-
v
Kiira Vuoristo, Kirsi Bromann, Mervi Toivari, Laura Ruohonen, Tiina Nakari-Setälä
2011
62)
n/a
-
v
Jakob B. Nielsen, Michael L. Nielsen, Christian Rank, Marie L.
Klejnstrup, Paiman Khorsand-Jamal, Dorte M. K. Holm, Bjarne G. Hansen, Jens C. Frisvad, Thomas O. Larsen and Uffe H. Mortensen2011
61)
n/a
-
v
Uffe H. Mortensen, Michael L. Nielsen, Jakob B. Nielsen,
Christian Rank, Marie L. Klejnstrup, Dorte K. Holm, Katrine H. Brogaard, Bjarne G. Hansen, Jens C. Frisvad, Thomas O. Larsen2011
NULL
n/a
-
v
Marie Louise Klejnstrup*, Morten
Thrane Nielsen, Jens Christian Frisvad, Uffe Mortensen, Thomas Ostenfeld Larsen. Department of Systems Biology,2011
NULL
n/a
-
v
Dorte K. Holm, Bjarne G. Hansen, Thomas O. Larsen, Uffe H. Mortensen
2011
NULL
n/a
-
v
.Outi M. Koivistoinen, Peter Richard, Merja Penttilä, Dominik
Mojzita2011
56)
n/a
-
v
Thomas O. Larsen*, C.
Rank, M. Klejnstrup, M.L. Nielsen, J.B. Nielsen, D.M.K. Holm, K.H. Brogaard, B. Hansen, J.C. Frisvad and U.H. Mortensen.2011
55)
n/a
-
v
Christian Rank*, Marie Louise Klejnstrup, Lene Maj Petersen, Jens Christian Frisvad,
Thomas Ostenfeld Larsen.2011
54)
n/a